13therapeutics Selected to Present at Prestigious University Research and Entrepreneurship Symposium

Share Article

13therapeutics will present its breakthrough technology at the prestigious University Research and Entrepreneurship Symposium (URES) 2012, the company and Oregon Health & Science University (OHSU) announced today. 13therapeutics' technology is one of 30 breakthrough innovations developed at world-class research universities from across the country that will be presented to an audience of New England’s top venture capitalists and entrepreneurs on April 18th, at the Microsoft NERD Center in Cambridge, Mass.

13therapeutics will present its breakthrough technology at the prestigious University Research and Entrepreneurship Symposium (URES) 2012, the company and Oregon Health & Science University (OHSU) announced today. 13therapeutics' technology is one of 30 breakthrough innovations developed at world-class research universities from across the country that will be presented to an audience of New England’s top venture capitalists and entrepreneurs on April 18th, at the Microsoft NERD Center in Cambridge, Mass. This selection marks the first time that an OHSU start-up company has been invited to present at URES.

“We are very pleased to have been chosen to present at the 2012 URES Conference," said Tom Bruggere Chairman and Chief Executive Officer of 13therapeutics. “The conference allows us to showcase our unique and important science to key participants in the biotech industry.”

13therapeutics has an innovative platform for discovering and enhancing peptides, derived from naturally occurring pathogens (e.g., bacteria, viruses and fungi), which modulate the human immune response. This platform has produced a portfolio of peptides with demonstrated immune-regulatory activity and with varying mechanisms of action. These peptides have potential application for treatment of both acute and chronic inflammatory diseases such as Rheumatoid Arthritis, Lupus, Cystic Fbrosis and Chron's Disease. The company is advancing it's lead compound, P13, for the topical treatment of Hearing Loss.

“13therapeutics’ success reflects the quality of research conducted at OHSU and the effectiveness of our commercialization efforts," said Tim Stout, M.D., Ph.D., M.B.A., OHSU vice president for technology transfer and business development. “We are gratified that URES has decided to showcase the company’s work and its important symposium.”

About URES

URES is an invitation-only one-day conference established to bring world-class technologies from university research to Boston to showcase them before a group of New England's top entrepreneurs and venture capitalists. The event will feature breakthrough technologies in three focus areas - information technology, life sciences and clean energy.

URES is presented by three leading venture capital firms ~ Flybridge Capital Partners, Atlas Ventures, and General Catalyst Partners along with sponsor Goodwin Procter and partner organizations NCET2 and Microsoft New England Research and Development Center. The one-day symposium has been designed to explore the challenges and opportunities faced by entrepreneurs and start-up companies commercializing university-owned technology while at the same time exposing New England's top venture capitalists and entrepreneurs to leading research universities beyond the Boston area.

About OHSU

Oregon Health & Science University is the state’s only health and research university and its only academic health center. As Portland's largest employer, OHSU's size contributes to its ability to provide many services and community support activities not found anywhere else in the state. OHSU serves patients from every corner of the state and is a conduit for learning for more than 4,300 students and trainees. OHSU is the source of more than 200 community outreach programs that bring health and education services to each county in the state. Oregon Health & Science University is the state’s only health and research university and its only academic health center. As Portland's largest employer, OHSU's size contributes to its ability to provide many services and community support activities not found anywhere else in the state. OHSU serves patients from every corner of the state and is a conduit for learning for more than 4,300 students and trainees. OHSU is the source of more than 200 community outreach programs that bring health and education services to each county in the state.

About 13therapeutics

13therapeutics is a research and drug development company identifying and characterizing novel anti- inflammatory peptide therapeutics for unmet medical needs with high commercial potential. Founded in 2008, the Portland, Oregon-based company is a spin-out from the Oregon Health and Science University (OHSU). The management team and research scientists of 13therapeutics are veterans of bioscience, research and technology.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tom Bruggerre

Elisa Williams
Visit website